-2.9 | | Rps12-ps9 | 'Mxd1 knockdown by siRNA' vs 'wild type' at '3 day' | phenotype, time | 3' RNA-seq of differentiating (brown) mouse subcutaneous SVF cells upon knockdown of Zfp521, Fhl1, or Mxd1 |
-2.7 | | Rps12-ps9 | 'Fhl1 knockdown by siRNA' vs 'wild type' at '3 day' | phenotype, time | 3' RNA-seq of differentiating (brown) mouse subcutaneous SVF cells upon knockdown of Zfp521, Fhl1, or Mxd1 |
-2.6 | | Rps12-ps9 | 'Fhl1 knockdown by siRNA' vs 'wild type' at '1 day' | phenotype, time | 3' RNA-seq of differentiating (brown) mouse subcutaneous SVF cells upon knockdown of Zfp521, Fhl1, or Mxd1 |
2.5 | | Rps12-ps9 | 'Triple knockout (Zfp36-/-, TNFR1-/-, TNFR2-/-)' vs 'wild type' | genotype | Transcription profiling by high throughput sequencing of douple (TNFR1-/-/TNFR2-/-) and triple (Zfp36-/-/TNFR1-/-/TNFR2-/-) knockout mouse spleens |
-2.5 | | Rps12-ps9 | 'Mxd1 knockdown by siRNA' vs 'wild type' at '1 day' | phenotype, time | 3' RNA-seq of differentiating (brown) mouse subcutaneous SVF cells upon knockdown of Zfp521, Fhl1, or Mxd1 |
2.4 | | Rps12-ps9 | 'undifferentiated' vs 'differentiated; rosiglitazone' in 'AKR/J' | phenotype, stimulus, strain | RNA-seq of mouse subcutaneous SVF cells before and after differentiation with a brown fat differentiation cocktail |
-2 | | Rps12-ps9 | 'Sox17.Epi' vs 'Sox17.Endo' | genotype | Transcription profiling by high throughput sequencing of Sox17.Epi and Endo cells from mouse embryos |
-1.6 | | Rps12-ps9 | 'tamoxifen induction at 2 months, wait 6 months' vs 'no tamoxifen induction' in 'basal cell of prostate epithelium; CK5-CreERT2 transgenic line' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
-1.5 | | Rps12-ps9 | 'tamoxifen induction at 2 months, wait 3 months' vs 'no tamoxifen induction' in 'basal cell of prostate epithelium; CK5-CreERT2 transgenic line' | cell type, genotype, growth condition | Transcription profiling by high throughput sequencing of PIN/tumor lesions from basal or luminal origins at time points at which mice displayed similar histopathological phenotypes |
1.3 | | Rps12-ps9 | 'Scara3 overexpression' vs 'wild type phenotype' | phenotype | RNA sequencing of Mus musculus T helper cell type 2 with retroviral overexpression of different genes |
1.3 | | Rps12-ps9 | 'epithelium-specific mutant beta-catenin expression' vs 'wild type' | phenotype | RNAseq of murine small intestinal tissue following epithelium-specific deletion of Bcl9/9l +/- Apc +/- mutant B-catenin |
1.3 | | Rps12-ps9 | 'Dmd-mdx mutation' vs 'wild type genotype' in 'none' | compound, genotype | RNA-seq comparison of fibro-adipogenic progenitors (FAPs) from wild type, mdx and cardiotoxin-injured mice |
1.2 | | Rps12-ps9 | 'cardiotoxin; 10 micromolar' vs 'none' in 'wild type genotype' | compound, genotype | RNA-seq comparison of fibro-adipogenic progenitors (FAPs) from wild type, mdx and cardiotoxin-injured mice |
-1 | | Rps12-ps9 | 'Ngn3-expressing cell' vs 'Ngn3-null cell' | cell type | Transcriptional profiling of Ngn3-dependent pancreatic endocrine differentiation at E15.5 |